April 1, 2009Expert Review of Cardiovascular Therapy
Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease
Key result
Perindopril reduces CV events in vascular disease via blood pressure-dependent and -independent mechanisms.
Why the study?
Perindopril has been extensively studied for cardiovascular disease treatment, but its blood pressure-independent cardioprotective effects across various vascular diseases require synthesis and clarification.
Does perindopril reduce cardiovascular events in patients with established vascular disease?
Population
Patients with hypertension, diabetes mellitus, cerebrovascular disease, stable CAD, and heart failure
Comparison
Perindopril or perindopril-based regimens versus placebo or standard care
Design
Review of randomized clinical trials
Authors
Discussion
Loading...
Member takes
Implication
Affirms perindopril efficacy in hypertension and vascular disease; reinforces consensus from prior RCTs for first-line consideration.
Structured PICO
Does perindopril reduce cardiovascular events in patients with established vascular disease?
P
Population
Patients with established vascular disease, hypertension, diabetes mellitus, cerebrovascular disease, stable coronary artery disease (CAD), and heart failure
I
Intervention
Perindopril or perindopril-based regimens
O
Outcome
Cardiovascular events
Perindopril provides blood pressure-independent cardioprotective effects, supporting its use based on vascular risk assessment rather than arbitrary blood pressure cut-offs.
Cite This Study
Brugts et al. (2009) conducted a review in Cardiovascular disease. Perindopril was evaluated. Perindopril provides blood pressure-dependent and -independent cardioprotective effects, reducing cardiovascular events in patients with established vascular disease.